<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03640026</url>
  </required_header>
  <id_info>
    <org_study_id>CHD045-17</org_study_id>
    <nct_id>NCT03640026</nct_id>
  </id_info>
  <brief_title>Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients</brief_title>
  <acronym>GLITTER</acronym>
  <official_title>Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes after kidney transplantation is a frequent complication, the incidence of which&#xD;
      varies from 7 to 45% depending on the studies and on the diagnostic criteria used.&#xD;
      Post-transplant diabetes is an early complication, most often occurring in the first month&#xD;
      after transplantation.&#xD;
&#xD;
      In addition to the additional health costs generated by the appearance of post-transplant&#xD;
      diabetes, the risk of graft loss is increased by 60% and the overall mortality risk by 90%.&#xD;
      Similarly, the development of glucose intolerance after transplantation is associated with&#xD;
      higher mortality.&#xD;
&#xD;
      Tacrolimus treatment is therefore currently one of the most important risk factors for&#xD;
      diabetes at the time of transplantation.&#xD;
&#xD;
      Indeed, several in vitro and in vivo animal studies have shown that tacrolimus alters&#xD;
      pancreatic endocrine function.&#xD;
&#xD;
      In the final stage, this cellular toxicity leads to diabetes, most often diagnosed on the&#xD;
      rise in capillary or venous blood sugar levels after transplantation. This diabetes often&#xD;
      requires hypoglycemic treatment with insulin or oral anti-diabetic drugs. for a variable&#xD;
      period. The pro-diabetogenic effect of tacrolimus is sometimes irreversible, justifying&#xD;
      preventive treatment.&#xD;
&#xD;
      No clinical studies have looked at &quot;sub-clinical&quot; changes in insulin secretion or insulin&#xD;
      resistance under tacrolimus prior to the onset of diabetes. The static indices HOMA-β% and&#xD;
      HOMA-IR (Homeostasis Model Accessment of insulin resistance) make it possible to estimate&#xD;
      insulin secretion and insulin resistance in fasting patients respectively, while the oral&#xD;
      glucose disposition index (IDO) makes it possible to study insulin secretion and action&#xD;
      dynamically (after a 75 g glucose load), and are calculated as follows:&#xD;
&#xD;
      HOMA IR= Fasting blood glucose (mmol/L) x Fasting insulin (mU/L)/ 22.5 HOMAβ% = 20 x fasting&#xD;
      insulinemia (mU/L) / fasting plasma glucose (mmol/L) - 3.5 IDO = (delta insulinemia T30-T0/&#xD;
      delta blood glucose T30-T0)/insulinemia T0&#xD;
&#xD;
      These indices have already been studied in dialysis patients (diabetic and non-diabetic) and&#xD;
      may allow a more detailed study of pancreatic response and insulin resistance under&#xD;
      tacrolimus in patients prior to renal transplantation. Determining the &quot;pancreatic response&quot;&#xD;
      to tacrolimus in patients prior to transplantation would prevent diabetes by adapting&#xD;
      immunosuppressive treatment and post-transplant screening modalities in the event of&#xD;
      pre-transplant subclinical abnormalities identified in our study. The development of&#xD;
      tacrolimus-induced diabetes in pre-transplantation in our study will be a contraindication to&#xD;
      tacrolimus at the time of transplantation and ciclosporin therapy will be preferred.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of haemodialysis patients modifying their glycemic profile receiving Tacrolimus</measure>
    <time_frame>During 14 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Tacrolimus treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.</description>
    <arm_group_label>Tacrolimus treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  1st Inscription on the kidney transplant list at Nantes University Hospital&#xD;
&#xD;
          -  Hemodialysis patient in one of the participating centres&#xD;
&#xD;
          -  Patient who is able to understand the proposed protocol and has given free and&#xD;
             informed consent&#xD;
&#xD;
          -  Patient with affiliation to the French social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal history of diabetes treated or untreated&#xD;
&#xD;
          -  Temporary contraindication for carcinological reasons&#xD;
&#xD;
          -  Hyperimmunized patient with an Ease of Access to Transplantation score &lt; 30&#xD;
&#xD;
          -  Immunosuppressive treatment in progress&#xD;
&#xD;
          -  Macrolide Allergies&#xD;
&#xD;
          -  Hypersensitivity to the excipients used in the composition of tacrolimus&#xD;
&#xD;
          -  Intolerance to the HGPO test&#xD;
&#xD;
          -  Progressive infectious outbreak&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Intercurrent infectious pathology&#xD;
&#xD;
          -  Patient under guardianship, curatorship, legal protection measure, or deprived of&#xD;
             liberty&#xD;
&#xD;
          -  Pregnant women, breastfeeding, or non-menopausal woman who refuses contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Awena LE FUR</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendée</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chloé MOREAU</last_name>
    <phone>0251446572</phone>
    <email>chloe.moreau@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Awena LE FUR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacques DANTAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

